Electric aircraft maker BETA Technologies said on Thursday it is partnering with Near Earth Autonomy to develop uncrewed aircraft for the military, with flight testing slated to begin in the first hal... ...

President Donald Trump's proposal to send out $2,000 "dividend†checks to show the benefits of his administration's tariffs keeps generating chatter in Washington, but some analysts are saying the payouts look unlikely. ...

Key TakeawaysIBM (IBM) and Cisco (CSCO) have announced a strategic collaboration to develop networked distributed quantum computing, targeting an initial demonstration within five years and a full network of large-scale, fault-tolerant quantum computers by the early 2030s.Mercedes F1 team principal Toto Wolff is reportedly selling a portion of his ownership stake to CrowdStrike (CRWD) CEO George Kurtz, in a deal that values the Formula One team at a record $6 billion.Google (parent company Alphabet Inc. (GO ...

Core Insights - Helmerich & Payne, Inc. (HP) is a prominent player in the oil and gas drilling industry, recognized for its specialized drilling services and a substantial fleet of land rigs both domestically and internationally [1] - RBC Capital has set a price target of $29 for HP, suggesting a potential price increase of 4.54% from its current trading price of $27.74 [1] - HP's stock price is currently at $27.81, reflecting a 2.22% increase or $0.61 from previous levels [2] Financial Performance - During the Q4 2025 earnings call, HP presented its financial standing with CEO John Lindsay and CFO J. Vann leading the discussion [2] - The stock has shown volatility, trading between $27.05 and $27.96 on the day, with significant fluctuations over the past year, reaching a high of $37.30 and a low of $14.65 [3] Market Position - HP has a market capitalization of approximately $2.76 billion, indicating its size and influence in the drilling sector [4] - The trading volume on the NYSE is 357,186 shares, reflecting active investor interest and providing insights into the company's market position and investor sentiment [4]

Nvidia (NVDA) stock fell along with the broader market on Thursday, despite the chipmaker posting better-than-expected third quarter earnings and providing a strong outlook for the current quarter a day earlier. Shares of Nvidia closed out the trading day down 3.15% after briefly turning higher at the start of the day. The company's "Magnificent Seven" compatriots also fell on the day. For the fourth quarter, Nvidia projects revenue of $65 billion plus or minus 2%. Wall Street was expecting revenue of $6 ...

The U.S. stock market experienced a day of significant volatility on Thursday, November 20th, 2025, as an initial surge fueled by Nvidia's strong earnings largely faded by the close, leaving major indexes in negative territory. Investors grappled with mixed signals from a delayed jobs report and shifting expectations around Federal Reserve policy, leading to a broad-based retreat from earlier gains.Major Index PerformanceAfter opening sharply higher on the heels of a blockbuster earnings report from artific ...

Nov 20, 2025 4:07 PM Eastern Standard Time Deadline Soon: Fortinet, Inc. (FTNT) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit Share LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 21, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Fortinet, Inc. ("Fortinet†or the "Company†) (NASDAQ: FTNT) common sto ...

Core Insights - Texas Attorney General Ken Paxton has filed a lawsuit against Bristol Myers Squibb and Sanofi, alleging that the companies failed to disclose the ineffectiveness of Plavix in preventing blood clots for certain patients [1] Company Summary - Bristol Myers Squibb and Sanofi are being accused of not providing adequate information regarding the efficacy of Plavix, a medication commonly used to prevent blood clots [1]

LONDON--(BUSINESS WIRE)--Perfect Moment Ltd. (NYSE American: PMNT) ("Perfect Moment†or the "Company†), the high-performance, luxury lifestyle brand that fuses technical excellence with fashion-led designs, today announced the appointment of Sharifa AlSudairi as a brand ambassador. Sharifa AlSudairi, a Saudi Arabian Alpine skier recognized by the International Ski Federation (FIS) and widely cited as the Kingdom's first female Alpine skier, brings competitive credibility and a pioneering spirit. ...

Core Insights - Crinetics Pharmaceuticals has initiated the pivotal Phase 3 CAREFNDR trial to evaluate the efficacy and safety of paltusotine for treating carcinoid syndrome associated with neuroendocrine tumors, building on positive Phase 2 results [1][2][3] Company Overview - Crinetics Pharmaceuticals is focused on developing transformative therapies for endocrine diseases and related tumors, with a core expertise in targeting G-protein coupled receptors [7][8] - The company’s lead product, paltusotine, is the first once-daily oral treatment approved for adults with acromegaly who have had an inadequate response to surgery [8] Clinical Trial Details - The CAREFNDR trial will enroll 141 adults with carcinoid syndrome, randomizing participants in a 2:1 ratio to receive either paltusotine 80 mg or a matching placebo [2] - The primary endpoint of the trial is to measure the change in flushing episodes per day from baseline to Week 12, with bowel movement frequency as a key secondary endpoint [2] - Following the 16-week randomized period, the trial includes a 104-week open-label extension to evaluate long-term efficacy and safety [2] Product Information - Paltusotine is a selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide currently in Phase 3 development for carcinoid syndrome, showing rapid and sustained reductions in symptoms during Phase 2 trials [5][6] - Approximately 20% of patients with neuroendocrine tumors experience carcinoid syndrome, characterized by symptoms such as diarrhea and flushing [6] Future Development - Crinetics is also exploring additional treatment options for neuroendocrine tumors through CRN09682, an investigational anti-tumor candidate that has received Investigational New Drug clearance [3]